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What’s new? 
 
• Real-time continuous glucose monitoring (RT-CGM) improves neonatal health 
outcomes, with fewer large for gestational age infants, fewer neonatal intensive care 
unit admissions and a shorter neonatal length of hospital stay 
• It is unknown whether the costs of implementing RT-CGM into NHS antenatal care, 
would be offset by the reduction in neonatal complications 
• The approximately 3-fold higher costs of RT-CGM use, compared with self-
monitoring of blood glucose (£1820 vs. £588), are offset by substantial cost savings, 
mainly through reductions in NICU admissions and a shorter duration of NICU stay 
 
Abstract 
Aim To investigate potential cost savings associated with the use of real-time continuous 
glucose monitoring (RT-CGM) throughout pregnancy in women with type 1 diabetes. 
Methods A budget impact model was developed to estimate, from the perspective of 
National Health Service England, the total costs of managing pregnancy and delivery in 
women with type 1 diabetes using self-monitoring of blood glucose (SMBG) with and 
without RT-CGM. It was assumed that the entire modelled cohort (n=1441) would use RT-
CGM from 10-38 weeks gestation (7 months). Data on pregnancy and neonatal complication 
rates and related costs were derived from published literature, national tariffs, and device 
manufacturers. 
Results The cost of glucose monitoring was £588 with SMBG alone and £1820 with RT-
CGM. The total annual costs of managing pregnancy and delivery in women with type 1 
diabetes were £23,725,648 with SMBG alone, and £14,165,187 with SMBG and RT-CGM; 
indicating potential cost savings of approximately £9,560,461 from using RT-CGM. The 
principal drivers of cost savings were the daily cost of neonatal intensive care unit (NICU) 
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admissions (£3743) and the shorter duration of NICU stay (mean 6.6 vs. 9.1 days 
respectively). Sensitivity analyses showed that RT-CGM remained cost saving, albeit to 
lesser extents, across a range of NICU costs and durations of hospital stay, and with varying 
numbers of daily SMBG measurements. 
Conclusions Routine use of RT-CGM by pregnant women with type 1 diabetes, would result 
in substantial cost savings, mainly through reductions in NICU admissions and shorter 
duration of NICU care.  
 
<H1>Introduction 
Type 1 diabetes during pregnancy is associated with increased risks of adverse outcomes 
such as pre-eclampsia, premature delivery, perinatal morbidity and admission to a neonatal 
intensive care unit (NICU) [1–4], which are at least partly attributable to suboptimal 
glycaemic control as measured by maternal glycated haemoglobin (HbA1c) levels [5]. For this 
reason, the UK National Institute for Health and Care Excellence (NICE) has recommended 
that glycaemic control should be optimized before and during pregnancy in women with type 
1 diabetes, with self-monitoring of blood glucose, at least four, and up to 10 times daily [6,7]. 
Despite frequent glucose monitoring optimal glucose control is often difficult to achieve due 
to pregnancy-related changes in insulin sensitivity and day-to-day variations in insulin 
pharmacokinetics with advancing gestation [8–10]. 
Real-time continuous glucose monitoring (RT-CGM) offers the potential to improve 
glycaemic control, compared with self-monitoring of blood glucose (SMBG), because it 
provides real-time data on changing glucose concentrations, thereby enabling users to take 
appropriate action in response to glucose fluctuations [11,12]. The potential value of this 
approach has been demonstrated in the Continuous Glucose Monitoring in Women with Type 
1 Diabetes in Pregnancy Trial (CONCEPTT), in which the use of RT-CGM, in addition to 
SMBG, resulted in improvements in time in glycaemic target ranges during the second and 
third trimesters. This was accompanied by improved neonatal outcomes such as fewer large 
for gestational age infants, fewer NICU admissions >24hrs, less neonatal hypoglycaemia, and 
a shorter duration of hospitalization, among infants of mothers using SMBG and RT-CGM 
[11]. Importantly, the treatment effect of RT-CGM was comparable in women receiving 
insulin pump therapy, and in those receiving multiple daily injections (MDI). This is 
consistent with the experience of RT-CGM users outside of pregnancy, and suggests that the 
potential benefits of RT-CGM are applicable to a broad population of people with type 1 
diabetes [13]. 
As RT-CGM and insulin delivery technologies are expensive, it is important to demonstrate 
the budgetary impact of these advancing technologies in clinical practice. Such evidence can 
be obtained through the use of budget impact models, which estimate the affordability of an 
intervention in a specific population over a short-term time horizon [14]. Our aim was to 
develop a budget impact model to estimate the costs and potential cost savings associated 
with the introduction of RT-CGM in pregnant women with type 1 diabetes. 
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<H1>Methods 
A model was developed to estimate, from the perspective of National Health Service (NHS) 
England, the costs associated with the use of RT-CGM by pregnant women with type 1 DM. 
It assumes that RT-CGM is used throughout pregnancy for approximately 28 weeks (from 
10-38 weeks gestation), and that neonates not admitted to a NICU stayed on a normal 
postnatal ward (Fig. 1). The model was constructed in Microsoft Excel, v1808 (Microsoft 
Corp, Redmond, WA, USA), and is available from the authors. 
<H2>Model inputs 
Model inputs are summarized in Table 1. Based on data from the 2014-2016 UK National 
Pregnancy Diabetes Audit, indicating 4323 pregnant women with type 1 diabetes over three 
years, we estimated that there were on average 1441 women per year throughout England 
[18]. Data on rates of complications (pre-eclampsia and NICU admission), durations of 
hospitalization or NICU stay, and frequency of glucose monitoring by RT-CGM or SMBG, 
were derived from CONCEPTT [11] and NICE guidance for the management of diabetes 
during pregnancy [6,7]. The indications for NICU admission and country-to-country NICU 
admission data were assessed posthoc after peer review. 
Neonates admitted to a NICU also had a stay in the postnatal ward, either before or after 
NICU admission. The duration of these stays was recorded, and if this was less than 24 hours 
the corresponding cost of the postnatal ward admission was not included in the cost 
calculation; hence, this calculation can be considered conservative. Based on data from 
CONCEPTT, it was assumed that women would use a mean of four CGM sensors per month, 
giving a total of 28 sensors between 10-38 weeks gestation. In addition, based on the NICE 
guidelines on pregnancy [NG3] and management of type 1 diabetes [NG17] [6,7], it was 
assumed from that women would make an average of 10 finger stick measurements per day if 
they were using SMBG alone, and four if they were using SMBG together with RT-CGM. 
Costs of managing complications and glucose monitoring were derived from the 2018/2019 
NHS National Tariffs [16], NICE guidance [6,7], a published clinical trial of glycaemic 
control in paediatric ICUs [15], and commercial data from Medtronic Ltd (Watford, UK). 
NICE data show that the mean costs of normal and complicated deliveries are £1957 and 
£3357 respectively, and hence the incremental cost of a complicated pregnancy, compared 
with normal pregnancy is £1400 [19]. Because the NICE guidance states that women with 
pre-eclampsia undergo deliveries with complications and comorbidities [7], this incremental 
cost was multiplied by the proportion of women with pre-eclampsia. Costs associated with 
the management of diabetes (e.g., costs of insulin therapy) were not included in the model 
which focuses on glucose monitoring rather than mode of insulin delivery. All costs are 
reported as 2018 GBP (£). 
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<H2>Sensitivity analyses 
The base case analysis assumed that 18% of deliveries would be complicated by pre-
eclampsia [11], the mean cost of NICU was £3743 per day, and that the mean duration of 
NICU care when RT-CGM was used with SMBG, compared to SMBG alone (6.6 vs. 9.1 
days, respectively) (unpublished CONCEPTT data). A number of sensitivity analyses were 
performed to determine the cost impact of varying different inputs. One-way analyses 
explored the impact of varying the proportion of complicated deliveries from 18% to 32%, 
and of varying the daily cost of NICU care from £3743 to £2400 or £3800. Two-way 
analyses investigated the potential cost impact of using between four and 12 blood glucose 
strips per day, and of durations of normal postnatal ward hospitalisation (excluding NICU) of 
between one and six days. It is now possible to use RT-CGM without SMBG, so the 
possibility of RT-CGM use with zero to four SMBG was assessed posthoc, after peer review.  
<H1>Results 
In the modelled population (n=1441), the total annual costs of glucose monitoring and the 
management of pregnancies and deliveries in women with type 1 diabetes were £23,725,648 
when glucose monitoring was performed by SMBG alone (Table S1). These costs decreased 
to £14,165,187 when it was assumed that the entire modelled cohort used RT-CGM together 
with SMBG during pregnancy (Fig. 2). Hence, the potential cost saving resulting from RT-
CGM use was approximately £9 560 461. The principal drivers of this saving were the daily 
cost of NICU care (£3743) and the shorter duration of NICU care when RT-CGM was used 
with SMBG, compared to SMBG alone (6.6 vs. 9.1 days, respectively). 
The main reasons for NICU admission were preterm delivery (63%), neonatal hypoglycaemia 
treated with iv dextrose (56%), neonatal hyperbilirubinemia (54%) and respiratory distress 
(26%), with comparable indications for NICU admission when RT-CGM was used with 
SMBG, compared to SMBG alone. The UK sites had the highest proportion of NICU 
admissions (63%), followed by Canada (34%) with only one or none in Spain, Italy, Ireland 
and the USA (Table S2).  
The impact of changes in complication rates and NICU costs on the potential cost savings 
achievable with RT-CGM was examined in sensitivity analyses. In the base case analysis, it 
was assumed that, in the absence of RT-CGM, 18% of deliveries would be complicated by 
pre-eclampsia. Increasing this proportion resulted in a progressive increase in the potential 
savings achievable with RT-CGM, which reached £9,842,896 with a complication rate of 
32%. Further analysis showed that RT-CGM was still cost-saving when the daily cost of 
NICU care was reduced from the base case value of £3743 to £2400 (potential saving 
£5,444,736), and that the savings increased to £9,735,141 when the daily cost was increased 
to £3800 (Fig. S1). 
Further sensitivity analyses examined the impact of SMBG strip use and length of non-NICU 
postnatal ward stay. The potential savings associated with RT-CGM use increased from 
approximately £9.1 million to £9.7 million when the mean number of daily finger stick 
measurements in the SMBG group was varied between four and 12, respectively (Table S3). 
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Furthermore, RT-CGM remained cost-saving, albeit to lesser extents, when the number of 
SMBG measurements in the RT-CGM users was increased from four to seven. In addition, 
greater cost savings were depicted when the number of SMBG measurements in the RT-
CGM users was reduced to zero demonstrating the potential savings of newer CGM systems 
with reduced and/or no need for additional SMBG tests. 
Similarly, decreasing the duration of postnatal (non-NICU) ward hospitalisation from three to 
one day, among RT-CGM users, increased the potential savings achievable (Fig. S2). The 
maximum potential saving was £11,145,546 when duration of non-NICU postnatal ward 
admission increased from three to six days in SMBG users and decreased from three to one 
days, among RT-CGM users (Table S4).  
<H1>Discussion 
This study has shown that the routine use of RT-CGM by pregnant women with type 1 
diabetes could produce savings to the NHS of approximately £9.6 million, mainly through 
reductions in NICU admissions and a shorter duration of NICU stay. Furthermore, RT-CGM 
remained cost saving, albeit to lesser extents, across a range of NICU daily costs, durations of 
NICU stay and varied number of daily SMBG measurements. Our model highlights the 
impact of NICU admissions on the total costs associated with the management of type 1 
diabetes during pregnancy. By contrast, the costs of postnatal ward admissions, in infants not 
admitted to NICU, and before or after NICU admission, account for smaller proportions of 
the total costs. 
In this budgetary impact model, the cost of RT-CGM use from 10-38 weeks gestation was 
approximately three-fold higher than that of SMBG alone (£1820 vs. £588 respectively), with 
the assumption that 10 SMBG measurements would be made per day in SMBG users [7]. 
Nevertheless, sensitivity analyses showed that RT-CGM still remained cost saving, when 
SMBG measurements were reduced to less than four per day.  
Furthermore, the observed savings may be under-estimates because we conservatively 
assumed that only 18% of pregnancies would be impacted by the additional costs associated 
with a complicated delivery (£3357 for complicated and £1957 for normal delivery [19]). 
Additional obstetric morbidities such as hypertensive disorders of pregnancy (any gestational 
hypertension, worsening of pre-existing hypertension) as well as maternal morbidity relating 
to large for gestational age birthweight (post-partum haemorrhage and perineal trauma) were 
not included with the incremental complicated delivery costs.  
Data on the cost-effectiveness of RT-CGM during pregnancy are scarce [19]. A recent 
systematic review [21] identified only two studies that directly compared CGM with capillary 
glucose monitoring [22,23], neither of which included cost data. It is noteworthy that in 
CONCEPTT, the numbers needed to treat with CGM to prevent one neonatal complication 
were low; six for NICU admissions and large for gestational age, and eight for neonatal 
hyperglycaemia [11]. This suggests that the potential cost savings seen in the present analysis 
are achievable. Furthermore, more than 50% of pregnant women in CONCEPTT were using 
multiple daily injections [11], and hence the costs of insulin treatment would have been lower 
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than with pump therapy. By contrast, in the Juvenile Diabetes Research Foundation study, 
approximately 90% of adults with type 1 diabetes, were using insulin pump therapy [24]. 
Importantly, clinical efficacy of RT-CGM in women using insulin pump therapy and multiple 
daily injections was comparable, although rates of NICU admission >24 hours were higher 
among insulin pump users [25]. However, the costs of insulin therapy were not included in 
our model, so we cannot draw conclusions about the potential costs of RT-CGM in women 
using pumps or multiple daily injections. 
Because type 1 diabetes during pregnancy is associated with increased risks of serious 
pregnancy complications such as congenital abnormalities, stillbirth, and neonatal mortality, 
it imposes particular clinical, societal and financial burdens on healthcare systems [26]. Large 
for gestational age remains the commonest complication, affecting half of all infants born to 
mothers with type 1 diabetes, and increases risk for obstetric complications including 
shoulder dystocia, instrumental and/or operative delivery and post-partum haemorrhage [27]. 
These costs are considered only in the duration of NICU and postnatal hospitalisation. Recent 
data confirm that the risk of adolescent obesity is 1.5 times higher in infants born large for 
gestational age [28], suggesting that the acceleration of BMI and sustained obesity persist 
throughout childhood and adolescence. The longer-term costs associated with childhood 
overweight and obesity attributable to large for gestational age birthweight in type 1 diabetes 
pregnancy are unknown.  
Strengths of the present study include the use of outcome data from a multicentre randomized 
controlled trial, robust sensitivity analyses and the use of contemporary National Diabetes 
Pregnancy data in the model. Approximately two-thirds of NICU admissions occurred in the 
UK making these data representative of the factors affecting NICU admission in the NHS. As 
well, the model inputs have been varied to reflect different scenarios of SMBG use and NICU 
costs, with RT-CGM found to be consistently cost saving. The reductions in large for 
gestational age neonates, neonatal hypoglycaemia and NICU admissions in RT-CGM users 
were generalizable across 31 centres from the UK, Canada, Spain, Italy, Ireland and the USA, 
so while there is no reason to assume that the potential for cost savings would vary 
substantially in different healthcare settings, they may be most applicable in settings with 
high NICU admission rates. The study has additional limitations. The modelled population is 
restricted to England, which may limit the generalizability of our findings, although 
pregnancy outcome data are comparable to studies from other Northern European, Canadian 
and USA healthcare settings [1,2,4,5,29,30]. A further potential limitation is that costs 
associated with the treatment of diabetes, such as diabetes educator time and costs of insulin 
therapy, were excluded from the model. As a result, it is not possible to determine whether, or 
to what extent, these costs affect the RT-CGM cost savings. Furthermore, the RT-CGM used 
during CONCEPTT has been superseded by newer CGM systems with a longer sensor 
lifespan. Recent improvements in sensor accuracy and reduced need for pre-meal SMBG 
and/or additional calibration tests, also mean that the current costs of glucose monitoring with 
modern CGM devices may now be lower. 
The results of this study have important implications for clinicians and policy makers. 
Current NICE guidance recommends that women with diabetes should aim to achieve an 
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HbA1c level of <48 mmol/mol (<6.5%) [6], but achieving this level of control throughout 
pregnancy is often difficult. It was achieved by only 40% of women with type 1 diabetes in 
England and Wales, with substantial variability across different maternity clinics [26]. By 
contrast, the NICE target HbA1c was achieved by 66% of women in CONCEPTT, with no 
heterogeneity across differing baseline maternal HbA1c levels or across countries. Pregnant 
women are often amongst the early adopters of advanced diabetes technologies, with data 
from the USA T1D Exchange clinic registry participants suggesting that approximately one 
third used CGM and three quarters used insulin pump therapy [29]. The Belgian healthcare 
authorities have authorized reimbursement of RT-CGM for insulin pump users with T1D 
treated in selected specialized diabetes centres. Initial data from over 500 users including 66 
women who were pregnant and/or planning pregnancy suggested potential for sustained 
improvements in glucose control for up to 12 months [30]. Inclusion of diabetes technology 
use (both RT-CGM and insulin pump therapy) as a key metrics in national and international 
Diabetes Pregnancy datasets is needed to determine whether the clinical and cost-
effectiveness demonstrated in CONCEPTT can be translated into real-world NHS clinical 
settings. 
In conclusion, our results suggest that the higher costs of RT-CGM, compared with SMBG 
alone, are offset by savings in NICU care. The cost savings associated with RT-CGM use are 
achieved mainly through reductions in NICU admission rates, and in the shorter length of 
NICU stay. This is an important message for clinicians and healthcare providers, given that 
40% of infants born to mothers with type 1 diabetes are admitted to NICU [26]. Routine use 
of RT-CGM by pregnant women with type 1 diabetes would result in substantial cost savings 
to the NHS, and probably to other healthcare systems. Recent improvements in sensor 
accuracy and duration mean that current RT-CGM use may result in more substantial cost 
savings. 
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FIGURE 1. Model design. CGM: continuous glucose monitoring; NICU: neonatal intensive care unit; SMBG: 
self-monitoring of blood glucose. 
FIGURE 2. Modelled cost of type 1 diabetes in pregnancy (10-38 weeks gestation) with real-time continuous 
glucose monitoring (RT-CGM) and self-monitoring of blood glucose (SMBG), compared to SMBG alone. 
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Additional Supporting Information is available in the online version of this article: 
Doc. S1. .Figure S1. Tornado plot showing results of one-way sensitivity analyses of the 
impact of varying neonatal intensive care unit costs from £2400 to £3800. 
Figure S2. Results of two-way sensitivity analyses showing impact of varying duration of 
postnatal ward care from 11 to 66 days for both cohorts 
Table S1. Costs of management of Type 1 diabetes pregnancies and deliveries, when glucose 
monitoring was performed with and without real-time continuous glucose monitoring. 
S..Table S2. Sensitivity analyses of the impact of changes in the daily number of SMBG 
measurements on the potential cost savings with RT-CGM use. 
Table S4. Sensitivity analyses of the impact of changes in the duration of neonatal hospital 
admission (postnatal ward without NICU) on the potential cost savings with RT-CGM use. 
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Table 1. Budget impact model inputs 
Complication rates RT-CGM + 
SMBG 
SMBG 
alone 
Source 
Admission to NICU > 24 h (%) 27 43 CONCEPTT [11] 
Mean length of stay in NICU (days) 6.6 9.1 CONCEPTT ‡  
Proportion of neonates admitted to NICU who 
also had a postnatal ward stay (%) 
57 42 CONCEPTT‡  
Number of days neonates admitted to NICU also 
had on a postnatal ward 
222 260  
Mean duration of postnatal ward care pre- or 
post-NICU admission (days) 
4.1 6.4 CONCEPTT‡  
Mean duration of hospitalization in neonates not 
admitted to NICU (days) 
3 3 CONCEPTT‡ 
Pre-eclampsia (%) 9 18 CONCEPTT [11] 
Costs Cost (£) Source 
NICU stay (24 h)  3743 Published data [15] 
Neonatal (non-NICU) bed stay (24 h)  347 NHS National Tariff [16] 
Incremental cost of delivery with complications 
(pre-eclampsia) 
1400 NHS National Tariff/NICE 
guidance [6,16] 
RT-CGM with SMBG    
RT-CGM costs    
Transmitter (replaced annually) £350 Manufacturer’s data* 
Sensor unit cost £52.50 Manufacturer’s data 
Number of sensors per month  4 CONCEPTT [11] 
Number of sensors per pregnancy†    28  
Total sensor cost per pregnancy  £1470  
Total RT-CGM cost per pregnancy £1820
SMBG costs 
Mean number of fingerstick measurements per 
day 
 4 NICE guidance [6,7] 
Cost per glucose strip £0.30 British National Formulary 
[17]  
Cost per day £1.20
Cost per month  £33.60  
Cost per pregnancy  £235.20  
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SMBG costs 
Mean number of fingerstick measurements per 
day 
 10  
Cost per glucose strip £0.30 British National Formulary 
[17] 
Cost per day £3
Cost per month  £84  
Cost per pregnancy  £588  
RT-CGM, real-time continuous glucose monitoring; SMBG, self-monitoring of blood glucose; NICU, neonatal 
intensive care unit; CONCEPTT, Continuous Glucose Monitoring in Women with Type 1 Diabetes in 
Pregnancy Trial; NICE, National Institute for Health and Care Excellence. 
*Manufacturer’s data provided by Medtronic Ltd (Watford, UK). 
†Assumed that RT-CGM is used for 7 months (from 10 to 38 weeks’ gestation) per pregnancy based on 
CONCEPTT [11]. 
‡Unpublished CONCEPTT data (provided by HR Murphy and DS Feig). 
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